FOUNDATIONONE®CDx

PATIENT	TUMOR TYPE	REPORT DATE
Chen, Jen-Huai	Brain anaplastic astrocytoma	11 Jan 2022
	COUNTRY CODE	ORDERED TEST #
	TW	ORD-1269425-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Brain anaplastic astrocytoma
NAME Chen, Jen-Huai
DATE OF BIRTH 21 February 1967
SEX Female
MEDICAL RECORD # 47841327

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN SITE Brain
SPECIMEN ID S110-38013 A (PF21075)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 03 December 2021
SPECIMEN RECEIVED 28 December 2021

Biomarker Findings
Microsatellite status - MS-Stable
Tumor Mutational Burden - 0 Muts/Mb

Genomic Findings
For a complete list of the genes assayed, please refer to the Appendix.

EGFR A289V
PTEN C105Y
CDKN2A/B CDKN2A rearrangement exon 2
RB1 R661W
SETD2 E2542fs*4
TERT promoter -124C>T

-----

† See About the Test in appendix for details.

Report Highlights

- Variants with **diagnostic implications** that may indicate a specific cancer type: *TERT* promoter -124C>T (p. 8)

- Targeted therapies with potential clinical benefit **approved in another tumor type**: Erlotinib (p. 9), Gefitinib (p. 9)

- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 10)

- Variants with **prognostic implications** for this tumor type that may impact treatment decisions: *TERT* promoter -124C>T (p. 8)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS	
Microsatellite status - MS-Stable	No therapies or clinical trials. see Biomarker Findings section	
Tumor Mutational Burden - 0 Muts/Mb	No therapies or clinical trials. see Biomarker Findings section	
GENOMIC FINDINGS	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
EGFR - A289V	none	Erlotinib
4 Trials *see p. 10*		Gefitinib
PTEN - C105Y	none	none
10 Trials *see p. 11*		

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

CDKN2A/B - CDKN2A rearrangement exon 2	p. 6	*SETD2* - E2542fs*4	p. 7
RB1 - R661W	p. 7	*TERT* - promoter -124C>T	p. 8

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

COUNTRY CODE
TW

REPORT DATE
11 Jan 2022

ORDERED TEST #
ORD-1269425-01

FOUNDATIONONE®CDx

Therapies contained in this report may have been approved by the US FDA.

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

ORDERED TEST # ORD-1269425-01

BIOMARKER FINDINGS

BIOMARKER
Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

MSI-High has been reported in 3-8% of adult or pediatric astrocytomas and was generally not associated with Lynch syndrome[6-8]. Low-level MSI has been reported in 5-9% of glioblastoma (GBM) samples[9-11]. A large-scale study did not find high-level microsatellite instability (MSI-H) in any of 129 GBM samples[9], although a small-scale study reported MSI-H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs[12]. The frequency of MSI has been reported to be increased in relapsed compared to primary GBM[9], in GBMs with a previous lower grade astrocytoma[10], and in giant cell GBM compared to classic GBM[11].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[13]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[13-15]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[16-18]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[13,15,17-18].

BIOMARKER
Tumor Mutational Burden

RESULT
0 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[19-21], anti-PD-1 therapies[19-22], and combination nivolumab and ipilimumab[23-28]. In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported[19,29-30]. However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti-PD-1[31-32] or anti-PD-L1[33] therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD-1 or PD-L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.

FREQUENCY & PROGNOSIS

Anaplastic astrocytoma harbors a median TMB of 1.8 mutations per megabase (muts/Mb), and 2% of cases have high TMB (>20 muts/Mb)[34]. For pediatric patients, high TMB has been reported in a subset of high-grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB[35-36]. Increased TMB has been reported to correlate with higher tumor grade in glioma[37] and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD)[31], as well as with shorter OS of patients with diffuse glioma[38].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[39-40] and cigarette smoke in lung cancer[41-42], treatment with temozolomide-based chemotherapy in glioma[43-44], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[45-49], and microsatellite instability (MSI)[45,48-49]. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[19,29-33].

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

GENOMIC FINDINGS

ORDERED TEST # ORD-1269425-01

GENE
EGFR

ALTERATION
A289V

TRANSCRIPT ID
NM_005228

CODING SEQUENCE EFFECT
866C>T

VARIANT ALLELE FREQUENCY (% VAF)
28.9%

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —
For patients with non-small cell lung cancer, EGFR activating mutations may predict sensitivity to EGFR TKIs, including erlotinib[50], gefitinib[51], afatinib[52], dacomitinib[53], and osimertinib[54]; however, the data for patients with other tumor types are limited[55-60]. A case study of a patient with multiple glioblastoma (GBM) tumors, one of which harbored EGFR amplification and multiple missense mutations, reported a near-CR of the EGFR-amplified and -mutated tumor to osimertinib[61]. A case series of 11 patients with bithalamic gliomas with EGFR mutations suggested that treatment with EGFR inhibitors, including osimertinib, prolonged patient survival relative to other types of treatment; however, no patients attained PR or SD[58].

FREQUENCY & PROGNOSIS
Across several genomic studies of CNS tumors, EGFR alterations have been reported in 13.2% of anaplastic astrocytomas, 5.3-15.9% of glioblastoma multiformes (GBMs), and 0% of pilocytic astrocytomas[62-65]. EGFR amplification and/or EGFR expression in glioma has been correlated with poor overall survival in patients under 60 years of age, prolonged survival in patients over the age of 60, and tumor grade[66-69].

FINDING SUMMARY
EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide[70]. The EGFR A289V mutation, located in the extracellular domain, has been shown to be activating[71]. Glioblastoma cell lines harboring an EGFR A289V or A289D mutation were shown to be dependent on EGFR kinase activity[72], and other mutations at this position are also likely activating. In addition, A289V is frequently associated with increased EGFR gene copy number[71].

ORDERED TEST # ORD-1269425-01

GENE
PTEN

ALTERATION
C105Y

TRANSCRIPT ID
NM_000314

CODING SEQUENCE EFFECT
314G>A

VARIANT ALLELE FREQUENCY (% VAF)
72.0%

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —
PTEN loss or mutation leads to activation of the PI3K-AKT-mTOR pathway and may predict sensitivity to inhibitors of this pathway[73-76]. Across various tissues, most clinical studies have not observed an association between PTEN deficiency and response to inhibitors of the PI3K-AKT-mTOR pathway. However, limited studies in prostate cancer[77-80], renal cell carcinoma[81], breast cancer[82-83], and colorectal cancer[84] have reported an association between PTEN deficiency and response to inhibitors targeting the PI3K-mTOR pathway. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors[85-89], and clinical benefit has been observed for patients with PTEN-altered breast cancer including triple negative breast cancer[90], ovarian cancer[91], uterine leiomyosarcoma[92], and endometrial cancer[89] treated with PARP inhibitors. However, some

studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity[93-94]. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.

— Potential Resistance —
In a retrospective analysis of 66 patients with glioblastoma, tumors from nivolumab or pembrolizumab non-responders were significantly enriched for PTEN mutations[29].

FREQUENCY & PROGNOSIS
Studies in the literature have indicated that PTEN alterations (mutation or homozygous deletion) occur most frequently in glioblastoma (GBM), less frequently in anaplastic astrocytoma, and rarely in lower grade glioma subtypes including low grade astrocytoma, oligodendroglioma, oligoastrocytoma, and ependymoma[66,95-101]. One study detected PTEN mutation in 42% (97/232) and loss in 10% (24/232) of IDH-wildtype GBM samples analyzed[102]. In the TCGA dataset, PTEN mutation was observed in 23% of GBM cases and PTEN deletion was reported in 7% of cases[63], while in the Lower Grade Glioma TCGA dataset, PTEN mutation was observed in 4% of cases and homozygous deletion observed in 1.2% of cases[103]. Loss of PTEN correlated with significantly worse prognosis in all grades of gliomas[98,104].

FINDING SUMMARY
PTEN encodes an inositol phosphatase that

functions as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis[74]. Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance.

POTENTIAL GERMLINE IMPLICATIONS
One or more of the PTEN variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hamartoma tumor syndrome (ClinVar, Sep 2021)[105]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte-Duclos disease (LD), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and Proteus-like syndrome[106-107]. The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients[106,108]. The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder[106]. Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

GENOMIC FINDINGS

ORDERED TEST # ORD-1269425-01

GENE
CDKN2A/B

ALTERATION
CDKN2A rearrangement exon 2

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib[109-112]. Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment[113-114], multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents[115-121]; it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors[122-123], the clinical relevance of p14ARF as a predictive biomarker is not clear.

— Potential Resistance —

Rb inactivation may predict resistance to CDK4/6 inhibitors such as palbociclib, abemaciclib, and ribociclib, which act upstream of Rb[124-133].

FREQUENCY & PROGNOSIS

Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas[64] and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)[63] than in those with lower grade gliomas (13%) (cBioPortal, Sep 2021)[134-135]. In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM)[136-138]. Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples[139]. Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression[137,140]. In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas[141-142].

FINDING SUMMARY

CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b[143-144]. Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control[145-146]. The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition[147-148]. One or more alterations observed here are predicted to result in p16INK4a loss of function[149-170]. One or more alterations seen here are predicted to result in p14ARF loss of function[153,170-173].

POTENTIAL GERMLINE IMPLICATIONS

Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer[174]. Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma[175-176]. CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases[177-179]. CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors[180-182]. In the appropriate clinical context, germline testing of CDKN2A is recommended.

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

GENOMIC FINDINGS

ORDERED TEST # ORD-1269425-01

GENE
RB1

ALTERATION
R661W

TRANSCRIPT ID
NM_000321

CODING SEQUENCE EFFECT
1981C>T

VARIANT ALLELE FREQUENCY (% VAF)
53.8%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of limited clinical data[183] and strong preclinical data[184-186], RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer. It should be noted that a trial of the Aurora kinase A inhibitor alisertib in advanced prostate cancer did not find an association between RB1 deletion and clinical benefit[187]. Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL-2 family members[188] and activation of the NOTCH pathway[189].

— Potential Resistance —

Rb inactivation may predict resistance to CDK4/6 inhibitors such as palbociclib, abemaciclib, and ribociclib, which act upstream of Rb[124-133].

— Nontargeted Approaches —

Loss of Rb function has been associated with increased sensitivity to cytotoxic agents and chemotherapeutics in both preclinical studies and in patients with bladder or breast cancer[190-191].

FREQUENCY & PROGNOSIS

In low-grade gliomas, alteration in the Rb pathway, including homozygous deletion and promoter methylation of CDKN2A, CDKN2B, and RB1, is reported to occur in 26% of cases lacking IDH1/2, TP53, or 1p/19q alterations, and in 11% of tumors harboring these alterations[192]. Loss of heterozygosity at the RB1 locus has been reported in 28-30% of high-grade astrocytomas, and specifically in 19% of anaplastic astrocytoma cases in one study[193-195]. Promoter hypermethylation of RB1 has also been observed in 6-19% of malignant astrocytomas, with one study citing RB1 promoter methylation in 14% of anaplastic astrocytomas[195-196]. In the TCGA datasets, RB1 mutation or homozygous deletion was observed in 9% of glioblastomas[63] and 2.5% of lower grade glioma cases[103]. In patients with low-grade diffuse gliomas, Rb pathway alterations have been significantly associated with poor clinical outcome[192,197].

FINDING SUMMARY

RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle[191,198]. Alterations such as seen here may disrupt RB1 function or expression[199-205].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the RB1 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with retinoblastoma (ClinVar, Sep 2021)[105]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year[206]. Germline mutations in RB1 account for approximately 40% of RB tumors[207] and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma[208-209]. In the appropriate clinical context, germline testing of RB1 is recommended.

GENE
SETD2

ALTERATION
E2542fs*4

TRANSCRIPT ID
NM_014159

CODING SEQUENCE EFFECT
7624_7625insG

VARIANT ALLELE FREQUENCY (% VAF)
39.0%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in SETD2.

FREQUENCY & PROGNOSIS

Somatic inactivating alterations of SETD2 are documented to occur at low frequency in a number of solid tumors, most commonly in renal carcinoma[210]. SETD2 has been associated with favorable prognosis in gastric cancer[211]. SETD2 has also been associated with poor prognosis in RCC and MDS[212], while data in other tumor types is limited (PubMed, Jun 2021).

FINDING SUMMARY

SETD2 encodes a histone lysine-36 methyltransferase[213] that preferentially interacts with the expanded N-terminal polyglutamine tracts present in mutant huntingtin, implicating it in the pathogenesis of Huntington disease[214]. SETD2 mRNA expression has been observed to be consistently reduced in breast tumors relative to adjacent non-tumor tissue, suggesting a potential tumor suppressor role[215]. Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance.

GENE

TERT

ALTERATION
promoter -124C>T

TRANSCRIPT ID
NM_198253

CODING SEQUENCE EFFECT
-124C>T

VARIANT ALLELE FREQUENCY (% VAF)
44.5%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor-associated antigen and antisense oligonucleotide- or peptide-based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials[216]; however, in one preclinical study, the combination of a TERT peptide vaccine and anti-CTLA-4 therapy suppressed tumor growth[217]. A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non-small cell lung cancer reported no improvement in PFS or OS[218].

FREQUENCY & PROGNOSIS

TERT promoter mutations have been reported in 51-59% of gliomas[219-220], most frequently in glioblastoma (GBM, 54-84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25-31%) but less frequently in lower grade astrocytomas (10-18%) and in only 1% of ependymomas[219-223]. TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM[224]. TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH-positive secondary GBM[219,221,224-225]. In the context of IDH-wildtype glioma, TERT mutations are associated with reduced OS, whereas in IDH-mutated, 1p/19q co-deleted oligodendroglioma, TERT mutations are associated with improved OS (NCCN CNS Cancers Guidelines, v5.2020).

FINDING SUMMARY

Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length[226]. Activation of TERT is a hallmark of cancer, being detected in up to 80-90% of malignancies and absent in quiescent cells[227-229]. Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at -124 bp and -146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)[230-232], as well as tandem mutations at positions –124/–125 bp and –138/–139 bp[230].

POTENTIAL DIAGNOSTIC IMPLICATIONS

TERT mutations are associated with 1p/19q co-deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX-wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v5.2020). Co-occurring TERT mutation, IDH mutation, and 1p/19q co-deletion is indicative of oligodendroglioma, whereas IDH mutation in the absence of TERT mutation is suggestive of astrocytoma (NCCN CNS Cancers Guidelines, v5.2020).

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

ORDERED TEST # ORD-1269425-01

THERAPIES WITH CLINICAL BENEFIT | IN OTHER TUMOR TYPE

Erlotinib

Assay findings association

EGFR
A289V

AREAS OF THERAPEUTIC USE
Erlotinib is a small-molecule inhibitor of EGFR. It is FDA approved as a monotherapy or in combination with ramucirumab for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations. Erlotinib is also FDA approved in combination with gemcitabine as a first-line treatment for advanced pancreatic cancer. Please see the drug label for full prescribing information.

GENE ASSOCIATION
Amplification or activation of EGFR may predict sensitivity to therapies such as erlotinib. For patients with activating mutations in EGFR, treatment with erlotinib has been associated with improved response and lengthened time to progression[50,233-235].

SUPPORTING DATA
In the MyPathway Phase 2a basket study for advanced solid tumors, 1 of 9 patients with EGFR activation mutations responded to erlotinib monotherapy; the responding patient had urethral adenocarcinoma[236]. A patient with EGFR-mutated metastatic lacrimal gland adenoid cystic carcinoma experienced clinical benefit from erlotinib treatment that was ongoing at 14 months[237]. A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response[238]. In a Phase 2 study of 65 patients with GBM or gliosarcoma, treatment with erlotinib, temozolomide, and radiotherapy resulted in longer progression-free survival relative to a historical control study utilizing a regimen of temozolomide and radiotherapy alone (19.3 months vs. 14.1 months)[239]. However, in a Phase 1/2 trial of erlotinib monotherapy in 11 patients with relapsed or refractory GBM or anaplastic astrocytoma, all patients showed disease progression and the drug showed significant toxicity[240]. In addition, a Phase 2 trial of patients with recurrent or progressive GBM treated with erlotinib and sorafenib did not meet its objective of a 30% increase in overall survival time compared with historical controls; sorafenib was found to increase erlotinib clearance[241].

Gefitinib

Assay findings association

EGFR
A289V

AREAS OF THERAPEUTIC USE
Gefitinib targets the tyrosine kinase EGFR and is FDA approved to treat non-small cell lung cancer (NSCLC) harboring exon 19 deletions or exon 21 (L858R) substitution mutations in EGFR. Please see the drug label for full prescribing information.

GENE ASSOCIATION
Activation of EGFR may predict sensitivity to therapies such as gefitinib. Clinical studies have consistently shown significant improvement in response rates and PFS for patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with gefitinib compared with chemotherapy[235,242-247], and responses have been reported for patients with EGFR-rearranged NSCLC[248-249].

SUPPORTING DATA
A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response[238]. A Phase 2 clinical study of gefitinib in patients with high-grade glioma (including GBM, anaplastic astrocytoma, and oligodendroglioma) reported 18% (5/28) disease stabilization; efficacy was not correlated with EGFR expression[250]. However, a Phase 1/2 clinical trial of gefitinib combined with radiotherapy in 178 patients with GBM reported no overall survival benefit of added gefitinib, and EGFR expression was found to be of no prognostic value for patients treated with gefitinib plus radiotherapy[251]. A Phase 2 trial of preoperative gefitinib treatment in patients with recurrent GBM reported that although EGFR phosphorylation was decreased in treated patients as compared to the control group, measurement of 12 downstream molecules revealed no significant changes[252].

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

CLINICAL TRIALS

ORDERED TEST # ORD-1269425-01

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
EGFR

ALTERATION
A289V

RATIONALE
EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.

NCT03239015

PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT03810872

PHASE 2

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

TARGETS
EGFR, ERBB4, ERBB2

LOCATIONS: Liège (Belgium), Brussels (Belgium), Gent (Belgium)

NCT02800486

PHASE 2

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

TARGETS
EGFR

LOCATIONS: New York

NCT03783403

PHASE 1

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

TARGETS
CD20, EGFR, SIRP-alpha

LOCATIONS: Heidelberg (Australia), Melbourne (Australia), Edmonton (Canada), California, Colorado, Arizona, Toronto (Canada), Oklahoma, Texas, Pennsylvania

FOUNDATIONONE®**CDx**

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

CLINICAL TRIALS

ORDERED TEST # ORD-1269425-01

GENE
PTEN

ALTERATION
C105Y

RATIONALE
PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.

NCT04337463

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

PHASE NULL

TARGETS
mTORC1, mTORC2, PD-1

LOCATIONS: Chongqing (China), Chengdu (China)

NCT04740190

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

PHASE 2

TARGETS
PARP

LOCATIONS: Hong Kong (Hong Kong)

NCT04001569

AZD8186 and Paclitaxel in Advanced Gastric Cancer

PHASE 1/2

TARGETS
PI3K-beta

LOCATIONS: Seongnam-si (Korea, Republic of)

NCT02264678

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

PHASE 1/2

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California

NCT03772561

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

PHASE 1

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

NCT04801966

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

PHASE NULL

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

CLINICAL TRIALS

ORDERED TEST # ORD-1269425-01

NCT03994796
PHASE 2

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

TARGETS
TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR

LOCATIONS: Alaska, Washington

NCT04632992
PHASE 2

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

TARGETS
TRKB, ALK, TRKC, ROS1, TRKA, PD-L1, ERBB2, ERBB3, PI3K-alpha, RET, AKTs

LOCATIONS: Alaska, Washington, Oregon, California, Montana

NCT04497116
PHASE 1/2

Study of RP-3500 in Advanced Solid Tumors

TARGETS
ATR, PARP

LOCATIONS: Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas

NCT03907969
PHASE 1/2

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers

TARGETS
PARP, DNA-PK

LOCATIONS: Newcastle upon Tyne (United Kingdom), London (United Kingdom), Connecticut, Texas

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

ORDERED TEST # ORD-1269425-01

APPENDIX | Variants of Unknown Significance

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

KDM5C
R179C

NTRK1
R220W

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

ORDERED TEST # ORD-1269425-01

APPENDIX   Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B)	APC
AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX	AURKA
AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2	BCL6
BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2
BTK	C11orf30 (EMSY)	C17orf39 (GID4)	CALR	CARD11	CASP8	CBFB	CBL	CCND1
CCND2	CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73
CDH1	CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B
CDKN2C	CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R
CTCF	CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1
DDR2	DIS3	DNMT3A	DOT1L	EED	EGFR	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRFI1	ESR1	EZH2
FAM46C	FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12
FGF14	FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3
FGFR4	FH	FLCN	FLT1	FLT3	FOXL2	FUBP1	GABRA6	GATA3
GATA4	GATA6	GNA11	GNA13	GNAQ	GNAS	GRM3	GSK3B	H3F3A
HDAC1	HGF	HNF1A	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDM5A	KDM5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKNK1	MLH1	MPL	MRE11A	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD3 (WHSC1L1)	NT5C2	NTRK1	NTRK2	NTRK3	P2RY8	PALB2
PARK2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)	PDGFRA
PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1	PMS2
POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI	PTCH1
PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51	RAD51B	RAD51C
RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	REL	RET
RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC	SDHD	SETD2
SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO	SNCAIP	SOCS1
SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3	STK11	SUFU
SYK	TBX3	TEK	TET2	TGFBR2	TIPARP	TNFAIP3	TNFRSF14	TP53
TSC1	TSC2	TYRO3	U2AF1	VEGFA	VHL	WHSC1	WT1	XPO1
XRCC2	ZNF217	ZNF703						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSPO2	SDC4	SLC34A2	TERC*	TERT**	TMPRSS2

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

ORDERED TEST # ORD-1269425-01

APPENDIX | About FoundationOne®CDx

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium.   CE

ABOUT FOUNDATIONONE CDX
FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE
FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES
FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT
Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance
FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)
An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials
Ranking of Therapies in Summary Table
Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials
Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION
Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations
1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-

FOUNDATIONONE®CDx

PATIENT	TUMOR TYPE	REPORT DATE
Chen, Jen-Huai	Brain anaplastic astrocytoma	11 Jan 2022

ORDERED TEST # ORD-1269425-01

APPENDIX | About FoundationOne®CDx

Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.

3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.

4. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.

5. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine

whether the patient is a candidate for biopsy.

6. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	%CV*
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

Interquartile Range = 1st Quartile to 3rd Quartile

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

ORDERED TEST # ORD-1269425-01

APPENDIX   About FoundationOne®CDx

cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED
Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT
This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT
Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN
Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.2.0

The median exon coverage for this sample is 977x

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

ORDERED TEST # ORD-1269425-01

APPENDIX   References

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Alonso M, et al. Cancer Res. (2001) pmid: 11280776
7. Rodríguez-Hernández I, et al. PLoS ONE (2013) pmid: 24073290
8. Vladimirova V, et al. Neuropathol. Appl. Neurobiol. (2008) pmid: 18053027
9. Martinez R, et al. Oncology (2004) pmid: 15331927
10. Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285
11. Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554
12. Szybka M, et al. Clin. Neuropathol. () pmid: 12908754
13. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
14. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
15. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
16. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
17. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
18. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
19. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
20. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
21. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
22. Cristescu R, et al. Science (2018) pmid: 30309915
23. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
24. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
25. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
26. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
27. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
28. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
29. Zhao J, et al. Nat. Med. (2019) pmid: 30742119
30. Touat M, et al. Nature (2020) pmid: 32322066
31. Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570
32. Johanns TM, et al. Cancer Discov (2016) pmid: 27683556
33. Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642
34. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
35. Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112
36. Johnson A, et al. Oncologist (2017) pmid: 28912153
37. Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864
38. Wang L, et al. BMC Cancer (2020) pmid: 32164609
39. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
40. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
41. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
42. Rizvi NA, et al. Science (2015) pmid: 25765070
43. Johnson BE, et al. Science (2014) pmid: 24336570
44. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
45. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
46. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
47. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
48. Nature (2012) pmid: 22810696

49. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
50. Rosell R, et al. Lancet Oncol. (2012) pmid: 22285168
51. Douillard JY, et al. Br. J. Cancer (2014) pmid: 24263064
52. Sequist LV, et al. J. Clin. Oncol. (2013) pmid: 23816960
53. Mok TS, et al. J. Clin. Oncol. (2018) pmid: 29864379
54. Jänne PA, et al. N. Engl. J. Med. (2015) pmid: 25923549
55. Hong MH, et al. Cancer (2020) pmid: 32749686
56. Kim HS, et al. Oncotarget (2015) pmid: 26462025
57. Kim HS, et al. Clin. Cancer Res. (2015) pmid: 25424851
58. Mondal G, et al. Acta Neuropathol (2020) pmid: 32303840
59. Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047
60. Chi AS, et al. JCO Precis Oncol (2020) pmid: 32923886
61. Makhlin I, et al. CNS Oncol (2019) pmid: 31769726
62. Jonsson P, et al. Clin. Cancer Res. (2019) pmid: 31263031
63. Brennan CW, et al. Cell (2013) pmid: 24120142
64. Ceccarelli M, et al. Cell (2016) pmid: 26824661
65. Thomas AA, et al. Neuro-oncology (2017) pmid: 28472509
66. Smith JS, et al. J. Natl. Cancer Inst. (2001) pmid: 11504770
67. Shinojima N, et al. Cancer Res. (2003) pmid: 14583498
68. Ambroise MM, et al. Asian Pac. J. Cancer Prev. (2010) pmid: 21133628
69. Hobbs J, et al. Am. J. Surg. Pathol. (2012) pmid: 22472960
70. Ciardiello F, et al. N. Engl. J. Med. (2008) pmid: 18337605
71. Lee JC, et al. PLoS Med. (2006) pmid: 17177598
72. Vivanco I, et al. Cancer Discov (2012) pmid: 22588883
73. Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938
74. Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521
75. Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108
76. Milella M, et al. Sci Rep (2017) pmid: 28220839
77. Templeton AJ, et al. Eur. Urol. (2013) pmid: 23582881
78. Sweeney C, et al. Lancet (2021) pmid: 34246347
79. de Bono JS, et al. Clin. Cancer Res. (2019) pmid: 30037818
80. Saura C, et al. Cancer Discov (2017) pmid: 27872130
81. Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302
82. André F, et al. J. Clin. Oncol. (2016) pmid: 27091708
83. Schmid P, et al. J. Clin. Oncol. (2019) pmid: 31841354
84. Weldon Gilcrease G, et al. Invest New Drugs (2019) pmid: 30302599
85. Mendes-Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735
86. Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923
87. Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244
88. McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328
89. Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130
90. Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536
91. Dougherty et al., 2014; ASCO Abstract 5536
92. Pan M, et al. Perm J (2021) pmid: 33970096
93. Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788
94. Romero I, et al. Gynecol Oncol (2020) pmid: 32988624
95. Zhou XP, et al. Int. J. Cancer (1999) pmid: 10096247
96. Rasheed BK, et al. Cancer Res. (1997) pmid: 9331072
97. Davies MP, et al. Br. J. Cancer (1999) pmid: 10188904
98. Lin H, et al. Clin. Cancer Res. (1998) pmid: 9796977
99. Schmidt EE, et al. J. Neuropathol. Exp. Neurol. (1999) pmid: 10560660
100. Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241

101. Furnari FB, et al. Genes Dev. (2007) pmid: 17974913
102. Yan et al. 2020; DOI:10.1200/PO.19.00385
103. Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751
104. Srividya MR, et al. Neuropathology (2011) pmid: 21134002
105. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
106. Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191
107. Orloff MS, et al. Oncogene (2008) pmid: 18794875
108. Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516
109. Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246
110. Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868
111. Cen L, et al. Neuro-oncology (2012) pmid: 22711607
112. Logan JE, et al. Anticancer Res. (2013) pmid: 23898052
113. Elvin JA, et al. Oncologist (2017) pmid: 28283584
114. Gao J, et al. Curr Oncol (2015) pmid: 26715889
115. Gopalan et al., 2014; ASCO Abstract 8077
116. Peguero et al., 2016; ASCO Abstract 2528
117. Konecny et al., 2016; ASCO Abstract 5557
118. DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126
119. Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798
120. Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767
121. Johnson DB, et al. Oncologist (2014) pmid: 24797823
122. Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101
123. Gamble LD, et al. Oncogene (2012) pmid: 21725357
124. Condorelli R, et al. Ann. Oncol. (2018) pmid: 29236940
125. Fry DW, et al. Mol. Cancer Ther. (2004) pmid: 15542782
126. Dean JL, et al. Oncogene (2010) pmid: 20473330
127. Dean JL, et al. Cell Cycle (2012) pmid: 22767154
128. Garnett MJ, et al. Nature (2012) pmid: 22460902
129. Roberts PJ, et al. J. Natl. Cancer Inst. (2012) pmid: 22302033
130. Patnaik A, et al. Cancer Discov (2016) pmid: 27217383
131. O'Leary B, et al. Cancer Discov (2018) pmid: 30206110
132. Costa C, et al. Cancer Discov (2019) pmid: 31594766
133. Chen SH, et al. Oncogene (2018) pmid: 29059158
134. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
135. Gao J, et al. Sci Signal (2013) pmid: 23550210
136. Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251
137. Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337
138. Weber RG, et al. Oncogene (2007) pmid: 16909113
139. Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817
140. Feng J, et al. Cancer (2012) pmid: 21713760
141. Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552
142. Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312
143. Quelle DE, et al. Cell (1995) pmid: 8521522
144. Mutat. Res. (2005) pmid: 15878778
145. Gazzeri S, et al. Oncogene (1998) pmid: 9484839
146. Oncogene (1999) pmid: 10498883
147. Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746
148. Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699
149. Ruas M, et al. Oncogene (1999) pmid: 10498896
150. Jones R, et al. Cancer Res. (2007) pmid: 17909018
151. Haferkamp S, et al. Aging Cell (2008) pmid: 18843795
152. Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717

FOUNDATIONONE®CDx

PATIENT
Chen, Jen-Huai

TUMOR TYPE
Brain anaplastic astrocytoma

REPORT DATE
11 Jan 2022

ORDERED TEST # ORD-1269425-01

APPENDIX   References

153. Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711
154. Gombart AF, et al. Leukemia (1997) pmid: 9324288
155. Yang R, et al. Cancer Res. (1995) pmid: 7780957
156. Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202
157. Greenblatt MS, et al. Oncogene (2003) pmid: 12606942
158. Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434
159. Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261
160. Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926
161. Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062
162. Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365
163. Koh J, et al. Nature (1995) pmid: 7777061
164. McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136
165. Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282
166. Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385
167. Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262
168. Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892
169. Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768
170. Rutter JL, et al. Oncogene (2003) pmid: 12853981
171. Itahana K, et al. Cancer Cell (2008) pmid: 18538737
172. Zhang Y, et al. Mol. Cell (1999) pmid: 10360174
173. Zhang Y, et al. Cell (1998) pmid: 9529249
174. Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917
175. Adv Exp Med Biol (2010) pmid: 20687502
176. Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083
177. De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703
178. Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650
179. Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243
180. Kaufman DK, et al. Neurology (1993) pmid: 8414022
181. Bahuau M, et al. Cancer Res (1998) pmid: 9622062
182. Chan AK, et al. Clin Neuropathol () pmid: 28699883
183. Owonikoko et al., 2016; ESMO Abstract 14230
184. Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631
185. Gong X, et al. Cancer Discov (2019) pmid: 30373917
186. Oser MG, et al. Cancer Discov (2019) pmid: 30373918
187. Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224

188. Allaman-Pillet N, et al. Ophthalmic Genet. () pmid: 21955141
189. Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955
190. Derenzini M, et al. Clin. Cancer Res. (2008) pmid: 18381962
191. Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056
192. Kim YH, et al. Brain Pathol. (2011) pmid: 21470325
193. Ichimura K, et al. Oncogene (1996) pmid: 8806696
194. Henson JW, et al. Ann. Neurol. (1994) pmid: 7979217
195. Gonzalez-Gomez P, et al. Br. J. Cancer (2003) pmid: 12556968
196. Ohta T, et al. Oncol. Rep. (2006) pmid: 17016577
197. Bäcklund LM, et al. Br. J. Cancer (2005) pmid: 15970925
198. Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841
199. Berge EO, et al. Mol. Cancer (2010) pmid: 20594292
200. Giacinti C, et al. Oncogene (2006) pmid: 16936740
201. Otterson GA, et al. Proc. Natl. Acad. Sci. U.S.A. (1997) pmid: 9342358
202. Otterson GA, et al. Am. J. Hum. Genet. (1999) pmid: 10486322
203. Qin XQ, et al. Genes Dev. (1992) pmid: 1534305
204. Rubin SM, et al. Cell (2005) pmid: 16360038
205. Sun H, et al. Mol. Cell. Biol. (2006) pmid: 16449662
206. Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159
207. Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621
208. Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478
209. Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033
210. Varela I, et al. Nature (2011) pmid: 21248752
211. Chen Z, et al. Biochem Biophys Res Commun (2018) pmid: 29522714
212. Chen BY, et al. Blood (2020) pmid: 32202636
213. Sun XJ, et al. J. Biol. Chem. (2005) pmid: 16118227
214. Faber PW, et al. Hum. Mol. Genet. (1998) pmid: 9700202
215. Al Sarakbi W, et al. BMC Cancer (2009) pmid: 19698110
216. Nat Rev Clin Oncol (2017) pmid: 27245281
217. Duperret EK, et al. Mol Ther (2018) pmid: 29249395
218. Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017
219. Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248
220. Killela PJ, et al. Oncotarget (2014) pmid: 24722048

221. Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565
222. Liu X, et al. Cell Cycle (2013) pmid: 23603989
223. Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961
224. Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841
225. Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890
226. Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685
227. Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118
228. Kim NW, et al. Science (1994) pmid: 7605428
229. Hanahan D, et al. Cell (2000) pmid: 10647931
230. Horn S, et al. Science (2013) pmid: 23348503
231. Huang FW, et al. Science (2013) pmid: 23348506
232. Vinagre J, et al. Nat Commun (2013) pmid: 23887589
233. Cappuzzo F, et al. Lancet Oncol. (2010) pmid: 20493771
234. Zhong WZ, et al. J. Clin. Oncol. (2019) pmid: 31194613
235. Petrelli F, et al. Clin Lung Cancer (2012) pmid: 22056888
236. Hainsworth JD, et al. J. Clin. Oncol. (2018) pmid: 29320312
237. Nie KK, et al. Chin Med J (Engl) (2018) pmid: 29998897
238. Mellinghoff IK, et al. N. Engl. J. Med. (2005) pmid: 16282176
239. Prados MD, et al. J. Clin. Oncol. (2009) pmid: 19075262
240. Kesavabhotla K, et al. J. Exp. Ther. Oncol. (2012) pmid: 22946346
241. Peereboom DM, et al. Neuro-oncology (2013) pmid: 23328813
242. Han JY, et al. J. Clin. Oncol. (2012) pmid: 22370314
243. Maemondo M, et al. N. Engl. J. Med. (2010) pmid: 20573926
244. Mitsudomi T, et al. Lancet Oncol. (2010) pmid: 20022809
245. Mok TS, et al. N. Engl. J. Med. (2009) pmid: 19692680
246. Qi WX, et al. Curr Med Res Opin (2015) pmid: 25329826
247. Zhao H, et al. J Thorac Oncol (2015) pmid: 25546556
248. Wang J, et al. Int. J. Cancer (2019) pmid: 30255937
249. Baik CS, et al. J Thorac Oncol (2015) pmid: 26398831
250. Franceschi E, et al. Br. J. Cancer (2007) pmid: 17353924
251. Chakravarti A, et al. Int. J. Radiat. Oncol. Biol. Phys. (2013) pmid: 23182702
252. Hegi ME, et al. Mol. Cancer Ther. (2011) pmid: 21471286

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531